We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Antibody Cocktail Blocks Growth of Drug-Resistant Lung Tumors in Mouse Model

By LabMedica International staff writers
Posted on 17 Jun 2015
Cancer researchers developed a cocktail of three monoclonal antibodies that was able to halt drug-resistant tumor growth in a mouse xenograft lung cancer model.

Lung cancer patients with primary epidermal growth factor receptor (EGFR) mutations usually respond well to treatment with targeted kinase inhibitors, but almost always develop drug acquire resistance, often due to a second-site mutation (T790M). More...
Clinical trials have tested the ability of a monoclonal antibody (mAb) to EGFR but failed to demonstrate any survival benefits despite the fact that the mAB should have blocked activation of the mutated receptor.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) traced the reason for this failure. By using cell lines with the T790M mutation, they discovered that prolonged exposure to mAbs against only the EGFR triggered molecular network rewiring by (i) stimulating the extracellular signal–regulated kinase (ERK) pathway; (ii) inducing the transcription of HER2 (human epidermal growth factor receptor 2) and HER3, which encode other members of the EGFR family, and the gene encoding HGF (hepatocyte growth factor), which is the ligand for the receptor tyrosine kinase MET, a molecule often expressed in metastatic cancers.

To counter the emergence of this new pathway, the investigators developed mAbs against HER2 and HER3. They reported in the June 2, 2015, online edition of the journal Science Signaling that supplementing the EGFR-specific mAb with those targeting HER2 and HER3 suppressed the compensatory feedback loops that had developed in cultured lung cancer cells. The triple mAb combination targeting all three receptors prevented the activation of ERK, accelerated the degradation of the receptors and inhibited the proliferation of tumor cells but not of normal cells. Furthermore, treatment with the antibody cocktail markedly reduced the growth of tumors in mice xenografted with cells that were resistant to combined treatment with erlotinib and the single function-blocking EGFR mAb.

"Treatment by blocking a single target can cause a feedback loop that ultimately leads to a resurgence of the cancer," said senior author Dr. Yosef Yarden, professor of molecular cell biology at the Weizmann Institute of Science. "If we can predict how the cancer cell will react when we block the growth signals it needs to continue proliferating, we can take preemptive steps to prevent this from happening."

Related Links:

Weizmann Institute of Science



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.